Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms

用于脑动脉瘤栓塞的重组丝弹性蛋白样蛋白聚合物

基本信息

批准号：
9542385
负责人：
Darwin Leroy Cheney
金额：
$ 15万
依托单位：
THERATARGET
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-15 至 2020-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9542385
关键词：
Address Aftercare Aneurysm Arteriovenous malformation Biocompatible Materials Biological Response Modifier Therapy Blood Blood flow Brain hemorrhage Catheters Cell Therapy Cells Cerebral Aneurysm Cerebrovascular system Cessation of life Characteristics Chronic Clinical Development Development Plans Disease Elastases Elastin Exposure to Foreign Bodies Formulation Fracture Functional disorder Gel Genetic Genetic Engineering Human Hydrogels Hypervascular In Vitro Inflammatory Injectable Injections Instruction Label Lead Liquid substance Mechanics Medical Care Costs Metals Modeling Molecular Weight Monitor Neck Nervous System Trauma Neurologic Symptoms Operative Surgical Procedures Organic solvent product Oryctolagus cuniculus Paralysed Performance Peripheral Pharmacotherapy Phase Physicians Polymers Polyvinyl Alcohol Preparation Protein Engineering Proteins Recombinant Proteins Recombinants Research Risk Rupture Ruptured Aneurysm Silk Small Business Technology Transfer Research Solid Solubility Structure Symptoms System Testing Therapeutic Therapeutic Embolization Thrombus Tissues Translating Treatment Protocols Vasculitis Vasospasm Wages Work aqueous base biomaterial compatibility cerebral artery cytotoxicity design healing hemodynamics improved in vivo in vivo Model insight iodixanol local drug delivery mechanical properties metallicity monomer next generation novel pressure prevent response risk minimization seal soft tissue standard of care tumor

项目摘要

NARRATIVE This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymer, SELP (silk-elastinlike protein)-815K, to embolize cerebral aneurysms. The SELP embolic would reduce the risk of aneurysm rupture while minimizing the risk of recanalization after treatment and providing a platform for delivering newly developed drugs or cell therapies directly to the aneurysmal sac. This work will result in an embolic that can potentially improve aneurysm healing, deliver therapeutics locally, and reduce the risks associated with the embolization of cerebral arteries.

叙述该STTR阶段提出的建议详细介绍了新型液体的基本原理和研究计划栓塞剂由基因工程蛋白聚合物，SELP（丝 - 叶酮样）组成蛋白质）-815K，栓塞脑动脉瘤。 SELP栓塞会降低动脉瘤的风险破裂，同时最大程度地降低治疗后的再新化风险，并提供一个平台来交付新开发的药物或细胞疗法直接针对动脉瘤囊。这项工作将导致栓塞可以潜在地改善动脉瘤愈合，在本地提供治疗剂，并降低与大脑动脉的栓塞。